A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis
Sponsor: Pfizer • ClinicalTrials.gov ID: NCT07470879
Recruiting for Similar Conditions?
Sponsors are looking for patients like you. See if you qualify for compensated research studies.
Check Eligibility →Description
The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in pediatrics participants (≥ 2 years up to \< 12 years of age). Participants who will complete the total 52-week treatment period will have the opportunity to continue in a Long-Term Extension (LTE) Period of up to 4 years (5 years after study enrollment).
Interventions
-
Etrasimod
(Drug)
Once daily by mouth
Eligibility criteria
Conditions
Locations
- Fink Children's Ambulatory Care Center — New York, New York, United States
- Kimmel Pavilion - NYU Langone — New York, New York, United States
- NYU Grossman School of Medicine — New York, New York, United States
- NYU Langone Health (Tisch Hospital) — New York, New York, United States
- NYU Langone Inflammatory Bowel Disease Center — New York, New York, United States
- NYU Langone Radiology - Tisch Hospital — New York, New York, United States
- NYU Medical Science Building (MSB) — New York, New York, United States
- The Children's Hospital at Westmead — Westmead, New South Wales, Australia
- Monash Health — Clayton, Victoria, Australia
- Perth Children's Hospital — Perth, Western Australia, Australia
- Health Sciences Centre Winnipeg — Winnipeg, Manitoba, Canada
- Children's Hospital Research Institute of Manitoba — Winnipeg, Manitoba, Canada
- CHU de Québec - Université Laval — Québec, Quebec, Canada
- Hospices Civils de Lyon - Hôpital Femme Mère Enfant — Bron, Auvergne-Rhône-Alpes, France
- Hôpital Universitaire Necker Enfants Malades — Paris, France
- Universitätsklinikum Münster - Albert Schweitzer Campus — Münster, North Rhine-Westphalia, Germany
- Universitätsklinikum Leipzig — Leipzig, Saxony, Germany
- Universitaetsklinikum Tuebingen — Tübingen, Germany
- HELIOS Klinikum Wuppertal — Wuppertal, Germany
- Sheba Medical Center — Ramat Gan, Central District, Israel
- Kaplan Medical Center Pharmacy — Rehovot, Central District, Israel
- Kaplan Medical Center — Rehovot, Central District, Israel
- Yitzhak Shamir Medical Center — Ẕerifin, Central District, Israel
- Shaare Zedek Medical Center — Jerusalem, Jerusalem, Israel
- Hadassah Medical Center — Jerusalem, Jerusalem, Israel
- Rambam Health Care Campus — Haifa, Northern District, Israel
- Carmel Medical Center — Haifa, Northern District, Israel
- Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII — Bergamo, Lombardy, Italy
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico — Milan, Lombardy, Italy
- Azienda Ospedaliera Universitaria Meyer IRCCS — Florence, Tuscany, Italy
- Saitama Prefectural Children's Medical Center — Saitama-shi, Saitama, Japan
- Japanese Red Cross Kumamoto Hospital — Kumamoto, Japan
- Juntendo University Hospital — Tokyo, Japan
- Centrum Zdrowia MDM — Warsaw, Masovian Voivodeship, Poland
- Medical Network Spółka z o.o. WIP Warsaw IBD Point Profesor Kierkuś — Warsaw, Masovian Voivodeship, Poland
- Gyncentrum sp. z o.o. NZOZ Holsamed - oddział Libero — Katowice, Poland
- Instytut "Pomnik - Centrum Zdrowia Dziecka" — Warsaw, Poland
- King's College Hospital — London, London, CITY of, United Kingdom
- Bristol Royal Hospital for Children — Bristol, United Kingdom
- Alder Hey Children's Hospital — Liverpool, United Kingdom
- Evelina London Children's Hospital — London, United Kingdom
- Sheffield Children's Hospital — Sheffield, United Kingdom
Partner with Nurenyx
Showcase your study to thousands of motivated patients matching your criteria.
Learn MoreOfficial Source
Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
View Official Record